Fina Biotech SL - Product Pipeline Analysis, 2018 Update
- GDME135820PD
- Pages: 26
- June 2018
- Region : Europe
- GlobalData
- Equity Research Report
- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
Summary
Fina Biotech SL (Fina), formerly Indas Biotech is a biotechnology projects developer that discovers new diagnostic and therapeutic techniques for the healthcare sector. The company finances, selects, develops, and markets biotechnology projects. It offers halosperm that is a kit to determine the degree of DNA fragmentation in human sperm. Fina also provides services to new tools for monitoring, diagnosis, prognosis and treatment of significant diseases and improve human health through the novelty carried out by Spanish researchers companies and research and development centers. The company's research areas include molecular diagnostics and stem cell therapies. It provides investments in the areas of oncology, cardiology and stem cell therapy. The company collaborates with public and private institutions, medical universities, and diagnostic laboratories. Fina is headquartered in Madrid, Spain.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Fina Biotech SL
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Fina Biotech SL Company Overview 4
Fina Biotech SL Company Snapshot 4
Fina Biotech SL Pipeline Products and Ongoing Clinical Trials Overview 4
Fina Biotech SL-Pipeline Analysis Overview 6
Fina Biotech SL-Key Facts 6
Fina Biotech SL-Major Products and Services 7
Fina Biotech SL Pipeline Products by Development Stage 8
Fina Biotech SL Ongoing Clinical Trials by Trial Status 10
Fina Biotech SL Pipeline Products Overview 11
Dx Bioenergetic Signature-Breast Cancer 11
Dx Bioenergetic Signature-Breast Cancer Product Overview 11
Dx Bioenergetic Signature-Colon Cancer 12
Dx Bioenergetic Signature-Colon Cancer Product Overview 12
Dx Bioenergetic Signature-Lung Cancer 13
Dx Bioenergetic Signature-Lung Cancer Product Overview 13
Dx Bladder Cancer 14
Dx Bladder Cancer Product Overview 14
Dx Bladder Cancer Clinical Trial 15
Dx Colon Cancer 16
Dx Colon Cancer Product Overview 16
Dx Prostate Cancer 17
Dx Prostate Cancer Product Overview 17
Dx Restenosis 18
Dx Restenosis Product Overview 18
Fina Biotech SL-Key Competitors 19
Fina Biotech SL-Key Employees 20
Fina Biotech SL-Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Fina Biotech SL, Recent Developments 22
Jan 26, 2017: Fina Biotech Receives two new patents in 2015 in the United States and in Canada, both belonging to the patent family BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD” 22
Jan 26, 2016: Fina Biotech Receives Patents both in US and Canada 22
Appendix 23
Methodology 23
About GlobalData 25
Contact Us 25
Disclaimer 26
List Of Figure
List of Figures
Fina Biotech SL Pipeline Products by Equipment Type 5
Fina Biotech SL Pipeline Products by Development Stage 8
Fina Biotech SL Ongoing Clinical Trials by Trial Status 10
List Of Table
List of Tables
Fina Biotech SL Pipeline Products and Ongoing Clinical Trials Overview 4
Fina Biotech SL Pipeline Products by Equipment Type 5
Fina Biotech SL Pipeline Products by Indication 5
Fina Biotech SL Ongoing Clinical Trials by Trial Status 5
Fina Biotech SL, Key Facts 6
Fina Biotech SL, Major Products and Services 7
Fina Biotech SL Number of Pipeline Products by Development Stage 8
Fina Biotech SL Pipeline Products Summary by Development Stage 9
Fina Biotech SL Ongoing Clinical Trials by Trial Status 10
Fina Biotech SL Ongoing Clinical Trials Summary 10
Dx Bioenergetic Signature-Breast Cancer-Product Status 11
Dx Bioenergetic Signature-Breast Cancer-Product Description 11
Dx Bioenergetic Signature-Colon Cancer-Product Status 12
Dx Bioenergetic Signature-Colon Cancer-Product Description 12
Dx Bioenergetic Signature-Lung Cancer-Product Status 13
Dx Bioenergetic Signature-Lung Cancer-Product Description 13
Dx Bladder Cancer-Product Status 14
Dx Bladder Cancer-Product Description 14
Dx Bladder Cancer-To evaluate the effectiveness of genetic markers in detection of bladder cancer. 15
Dx Colon Cancer-Product Status 16
Dx Colon Cancer-Product Description 16
Dx Prostate Cancer-Product Status 17
Dx Prostate Cancer-Product Description 17
Dx Restenosis-Product Status 18
Dx Restenosis-Product Description 18
Fina Biotech SL, Key Employees 20
Glossary 24
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
Fina Biotech SL,Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
Laboratorios SALVAT SA
Histocell SL
Applied Research using OMIC Sciences SL
Related Reports
Page 152 | 
May 2019
Page 91 | December 2018
Page 40 | June 2018
Page 102 | June 2018
Page 54 | February 2018
